Specialty Pharmaceutical Industry - 2011 Yearbook


#3264

168pages

GBI Research

$ 3500

In Stock


GBI Research's "Specialty Pharmaceutical Industry - 2011 Yearbook essentially provides insights on specialty pharmaceutical sales and price forecasts until 2017. The report provides in-depth therapeutics analysis of eight niche indications, namely: Human Immunodeficiency Virus (HIV)/Acquired immune deficiency syndrome (AIDS), age related macular degenerative disorders, attention deficit hyperactivity disorder (ADHD), Alzheimers disease, colorectal cancer, rheumatoid arthritis, epilepsy and glaucoma, including their annual cost of therapy (ACT) and revenue. 

In addition, the geographical distribution of these disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the specialty pharmaceutical Research and Development (R&D) pipeline and the potential future blockbusters up to 2017. 

Furthermore, it also covers the market forecasts and treatment usage patterns of these eight therapeutic indications up to 2017. Finally, the key trend analysis on Mergers and Acquisitions (M&A), licensing agreements and co-development deals involving specialty pharmaceuticals is also presented.

Scope

The report covers - 

  • Annualized market data for the specialty pharmaceutical market from 2001 to 2009, with forecasts to 2017.
  • Market analysis for the eight major indications in the global specialty pharmaceutical market which includes HIV/AIDS, age related macular degenerative disorder, attention deficit hyperactivity disorder (ADHD), Alzheimers disease, colorectal cancer, rheumatoid arthritis, epilepsy and glaucoma.
  • Data and analysis on the specialty pharmaceutical market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
  • Key M&A activities and licensing agreements that took place from 2004 to 2010 in the specialty pharmaceutical market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to - 

  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
Table of Contents

1 Table of Contents

1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 9

2 Specialty Pharmaceutical Market- 2011 Yearbook: Introduction 12
2.1 Scope 12
2.2 GBI Research Report Guidance 12

3 Specialty Pharmaceutical Market- 2011 Yearbook: HIV Therapeutics Market 13
3.1 Disease Overview 13
3.2 Market Overview 14
3.3 Global HIV Therapeutics Market: Market Characterization 14
3.3.1 Market Forecasts 14
3.3.2 Annual Cost of Therapy 16
3.3.3 Usage Patterns 18
3.3.4 Geographical Distribution 24
3.4 HIV Therapeutics Market: Drivers and Restraints 26
3.4.1 Market Drivers 26
3.4.2 Market Restraints 29

4 Specialty Pharmaceutical Market- 2011 Year Book: Age Related Macular Degenerative Disorder 31
4.1 Disease Overview 31
4.2 Market Overview 31
4.3 Age Related Macular Degenerative Disorder: Market Characterization 32
4.3.1 Market Forecasts 32
4.3.2 Geographical Distribution 33
4.3.3 Annual Cost of Therapy 34
4.3.4 Usage Patterns 35
4.4 Age Related Macular Degenerative Disorder: Drivers and Restraints 39
4.4.1 Market Drivers 39
4.4.2 Market Restraints 40

5 Specialty Pharmaceutical Market- 2011 Yearbook: Attention Deficit Hyperactive Disorder (ADHD) 41
5.1 Introduction 41
5.2 Attention Deficit Hyperactive Disorder: Market Characterization 41
5.2.1 Market Forecasts 41
5.2.2 Geographical Distribution 43
5.2.3 Annual Cost of Therapy 44
5.2.4 Usage Patterns 45
5.3 Attention Deficit Hyperactive Disorder Market: Drivers and Restraints 50
5.3.1 Market Drivers 50
5.3.2 Market Restraints 50

6 Specialty Pharmaceutical Market- 2011 Yearbook: Alzheimers Disease 51
6.1 Introduction 51
6.2 Alzheimers disease: Market Characterization 51
6.2.1 Market Forecasts 51
6.2.2 Geographical Distribution 53
6.2.3 Annual Cost of Therapy 54
6.2.4 Usage Patterns 55
6.3 Alzheimers Disease Market: Drivers and Restraints 60
6.4 Market Drivers 60
6.5 Market Restraints 60

7 Specialty Pharmaceutical Market- 2011 Yearbook: Colorectal Cancer 61
7.1 Introduction 61
7.2 Colorectal Cancer: Market Characterization 61
7.2.1 Market Forecasts 61
7.2.2 Geographical Distribution 63
7.2.3 Annual Cost of Therapy 64
7.2.4 Usage Patterns 65
7.3 Colorectal Cancer Market: Drivers and Restraints 70
7.3.1 Market Drivers 70
7.3.2 Market Restraints 70

8 Specialty Pharmaceutical Market- 2011 Yearbook: Rheumatoid Arthritis 71
8.1 Introduction 71
8.2 Rheumatoid Arthritis: Market Characterization 71
8.2.1 Market Forecasts 71
8.2.2 Annual Cost of Therapy 73
8.2.3 Treatment Usage Patterns 74
8.2.4 Geographical Distribution 79
8.3 Rheumatoid Arthritis Market: Drivers and Restraints 80
8.3.1 Market Drivers 80
8.3.2 Market Restraints 80

9 Specialty Pharmaceutical Market- 2011 Yearbook: Epilepsy 81
9.1 Introduction 81
9.2 Epilepsy: Market Characterization 81
9.2.1 Market Forecasts 81
9.2.2 Geographical Distribution 83
9.2.3 Annual Cost of Therapy 84
9.2.4 Usage Patterns 85
9.3 Epilepsy Market: Drivers and Restraints 90
9.3.1 Market Drivers 90
9.3.2 Market Restraints 90

10 Specialty Pharmaceutical Market- 2011 Yearbook: Glaucoma 91
10.1 Introduction 91
10.2 Glaucoma: Market Characterization 91
10.2.1 Market Forecasts 91
10.2.2 Geographical Distribution 93
10.2.3 Annual Cost of Therapy 94
10.2.4 Usage Patterns 95
10.3 Glaucoma Market: Drivers and Restraints 100
10.3.1 Drivers of the Glaucoma Market 100
10.3.2 Barriers for the Glaucoma Market 100

11 Specialty Pharmaceutical Market- 2011Yearbook: Pipeline Analysis 102
11.1 Specialty Pharmaceutical Pipeline: HIV market 105
11.2 Molecule Profile for Promising Drugs under Clinical Development: HIV 106
11.2.1 Rilpivirine hydrochloride (TMC278) 106
11.2.2 Elvitegravir 107
11.2.3 Elvitegravir/GS-9350/Emtricitabine/Tenofovir (Quad) 108
11.2.4 Racivir 109
11.2.5 Apricitabine (ATC) 110
11.2.6 Tesamorelin 111
11.3 Specialty Pharmaceutical Pipeline: Age Related Macular Degeneration 112
11.4 Molecule Profile for Promising Drugs under Clinical Development: Age Related Macular Degeneration 113
11.4.1 VEGF Trap-Eye 113
11.5 Specialty Pharmaceutical Pipeline: Attention Deficit Hyperactive Disorder 114
11.6 Molecule Profile for Promising Drugs under Clinical Development: Attention Deficit Hyperactive Disorder 115
11.6.1 ABT-894 (Sofinicline) 115
11.6.2 Eltoprazine 115
11.6.3 AZD3480 (TC-1734) (Isopronicline) 116
11.7 Specialty Pharmaceutical Pipeline: Alzheimers Disease 117
11.8 Molecular Profile for the Promising Drugs under Clinical Development: Alzheimers Disease 118
11.8.1 Bapineuzumab 118
11.8.2 Gammagard 119
11.8.3 Dimebon 120
11.8.4 Rember (Trx0014) (methylthionium chloride) 120
11.9 Specialty Pharmaceutical Pipeline: Colorectal Cancer 122
11.10 Molecule Profile for Promising Drugs under Clinical Development: Colorectal Cancer 123
11.10.1 Aflibercept 123
11.10.2 Brivanib 124
11.10.3 OncoVAX 125
11.10.4 TroVax 127
11.10.5 KRX-0401 (Perifosine) 128
11.11 Specialty Pharmaceutical Pipeline: Rheumatoid Arthritis 129
11.12 Profiles for Promising Drugs under Clinical Development: Rheumatoid Arthritis 130
11.12.1 T-614 (iguratimod) 130
11.12.2 CP-690550 130
11.12.3 Arzerra (HuMax-CD20 /Ofatumumab) 131
11.12.4 VX-509 132
11.13 Specialty Pharmaceutical Pipeline: Epilepsy 133
11.14 Molecule Profile for Promising Drugs under Clinical Development: Epilepsy 134
11.14.1 Stedesa (Eslicarbazepine Acetate) 134
11.14.2 Comfyde (Carisbamate) 135
11.14.3 Retigabine 136
11.14.4 Brivaracetam 137
11.14.5 Ganaxolone 137
11.14.6 E2007 (Perampanel) 138
11.15 Specialty Pharmaceutical Pipeline: Glaucoma 139
11.16 Molecule Profile for Promising Drugs under Clinical Development: Glaucoma 140
11.16.1 Tafluprost (Saflutan) 140
11.16.2 NCX-116 (Formerly PF-03187207) 141

12 Specialty Pharmaceutical Market- 2011 Yearbook: Strategic Consolidations 142
12.1 Mergers and Acquisitions 142
12.1.1 Pfizer 144
12.1.2 F. Hoffmann-La Roche 146
12.1.3 GlaxoSmithKline 146
12.2 Licensing Deals 148
12.2.1 Pfizer 149
12.2.2 F. Hoffmann-La Roche 151
12.2.3 GlaxoSmithKline 153
12.3 Co-Development Deals 155
12.3.1 Pfizer 156
12.3.2 F. Hoffmann-La Roche 158
12.3.3 GlaxoSmithKline 160

13 Specialty Pharmaceutical Market- 2011 Yearbook: Appendix 162
13.1 Market Definitions 162
13.2 Abbreviations 162
13.3 Research Methodology 163
13.3.1 Coverage 163
13.3.2 Secondary Research 164
13.3.3 Primary Research 164
13.3.4 Forecasts 164
13.3.5 Expert Panel Validation 167
13.4 Contact Us 167
13.5 Disclaimer 167
13.6 Sources 167
Table 1: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Revenue ($m), 20012009 15
Table 2: Specialty Pharmaceutical Market, HIV Market, Global, Revenue ($m), 20092017 15
Table 3: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 16
Table 4: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2017 17
Table 5: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Usage Patterns, 20012009 19
Table 6: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Usage Patterns, 20012009 19
Table 7: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Market Size ($m), by countries, 2001-2009 24
Table 8: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Market Size ($m), by countries, 2009-2017 24
Table 9: HIV Therapeutics Market, Global, Key Drugs Going Off Patent, 20082016 29
Table 10: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Revenue ($m), 2001-2009 32
Table 11: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Revenue ($m), 2009-2017 32
Table 12: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Geographical Distribution of Revenues , 20012009 33
Table 13: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Geographical Distribution of Revenues, 20102017 33
Table 14: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Annual Cost of Therapy ($), 2001-2009 34
Table 15: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Annual Cost of Therapy ($), 2009-2017 34
Table 16: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Usage Patterns, 20012009 35
Table 17: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Usage Patterns, 20092017 35
Table 18: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Revenue ($m), 2001-2009 42
Table 19: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Revenue ($m), 2009-2017 42
Table 20: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Geographical Distribution of Revenues ($m), 20012009 43
Table 21: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Geographical Distribution of Revenues ($m), 20092017 43
Table 22: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Annual Cost of Therapy ($), 2001-2009 44
Table 23: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Annual Cost of Therapy ($), 2009-2017 44
Table 24: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Usage Patterns, 20012009 45
Table 25: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Usage Patterns, 20092017 45
Table 26: Specialty Pharmaceutical Market, Alzheimers Disease, Global, Revenue ($m), 2001-2009 51
Table 27: Specialty Pharmaceutical Market, Alzheimers Disease, Global, Revenue ($m), 2009-2017 52
Table 28: Specialty Pharmaceutical Market, Alzheimers Disease, Global, Geographical Distribution of Revenues ($m), 20012009 53
Table 29: Specialty Pharmaceutical Market, Alzheimers Disease, Global, Geographical Distribution of Revenues ($m), 20092017 53
Table 30: Specialty Pharmaceutical Market, Alzheimers Disease, Global, Annual Cost of Therapy ($), 2001-2009 54
Table 31: Specialty Pharmaceutical Market, Alzheimers Disease, Global, Annual Cost of Therapy ($), 2009-2017 54
Table 32: Specialty Pharmaceutical Market, Alzheimers Disease, Global, Usage Patterns, 20012009 55
Table 33: Specialty Pharmaceutical Market, Alzheimers Disease, Global, Usage Patterns, 20092017 55
Table 34: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Revenue ($m), 2001-2009 62
Table 35: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Revenue ($m), 2009-2017 62
Table 36: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Geographical Distribution of Revenues ($m), 20012009 63
Table 37: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Geographical Distribution of Revenues ($m), 20092017 63
Table 38: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Annual Cost of Therapy ($), 2001-2009 64
Table 39: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Annual Cost of Therapy ($), 2009-2017 64
Table 40: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Usage Patterns, 20012009 65
Table 41: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Usage Patterns, 20092017 66
Table 42: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Revenue ($m), 2001-2009 72
Table 43: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Revenue ($m), 2009-2017 72
Table 44: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2001-2009 73
Table 45: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2009-2017 73
Table 46: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Usage Patterns, 20012009 74
Table 47: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Usage Patterns, 20092017 74
Table 48: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Geographical Distribution of Revenues ($m), 20012009 79
Table 49: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Geographical Distribution of Revenues ($m), 20092017 79
Table 50: Specialty Pharmaceutical Market, Epilepsy, Global, Revenue ($m), 2001-2009 82
Table 51: Specialty Pharmaceutical Market, Epilepsy, Global, Revenue ($m), 2009-2017 82
Table 52: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($m), 20012009 83
Table 53: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($m), 20092017 83
Table 54: Specialty Pharmaceutical Market, Epilepsy, Global, Annual Cost of Therapy ($), 2001-2009 84
Table 55: Specialty Pharmaceutical Market, Epilepsy, Global, Annual Cost of Therapy ($), 2009-2017 84
Table 56: Specialty Pharmaceutical Market, Epilepsy, Global, Usage Patterns, 20012009 85
Table 57: Specialty Pharmaceutical Market, Epilepsy, Global, Usage Patterns, 20092017 85
Table 58: Specialty Pharmaceutical Market, Glaucoma, Global, Revenue ($m), 2001-2009 92
Table 59: Specialty Pharmaceutical Market, Glaucoma, Global, Revenue ($m), 2009-2017 92
Table 60: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($m), 20012009 93
Table 61: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($m), 20092017 93
Table 62: Specialty Pharmaceutical Market, Glaucoma, Global, Annual Cost of Therapy ($), 2001-2009 94
Table 63: Specialty Pharmaceutical Market, Epilepsy, Global, Annual Cost of Therapy ($), 2009-2017 94
Table 64: Specialty Pharmaceutical Market, Glaucoma, Global, Usage Patterns, 20012009 95
Table 65: Specialty Pharmaceutical Market, Glaucoma, Global, Usage Patterns, 20092017 96
Table 66: Specialty Pharmaceutical Market, M&A, Pfizer, 2004 to 2010 144
Table 67: Specialty Pharmaceutical Market, M&A, F. Hoffmann-La Roche, 2004 to 2010 146
Table 68: Specialty Pharmaceutical Market, M&A, GlaxoSmithKline, 2004 to 2010 146
Table 69: Specialty Pharmaceutical Market, Licensing Deals, Pfizer, 2004 to 2010 149
Table 70: Specialty Pharmaceutical Market, Licensing Deals , F. Hoffmann-La Roche, 2004 to 2010 151
Table 71: Specialty Pharmaceutical Market, Licensing Deals, GlaxoSmithKline, 2004 to 2010 153
Table 72: Specialty Pharmaceutical Market, Co-development Deals, Pfizer, 2004-2010 156
Table 73: Specialty Pharmaceutical Market, Co-development Deals, F. Hoffmann-La Roche, 2004-2010 158
Table 74: Specialty Pharmaceutical Market, Co-development Deals, GlaxoSmithKline, 2004-2010 160
Figure 1: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Market Size ($m), 2001-2017 14
Figure 2: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2017 16
Figure 3: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Usage Patterns, 20002016 18
Figure 4: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Diseased Population, 20012017 20
Figure 5: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Treatment Seeking Population, 20012017 21
Figure 6: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Diagnosis Population, 20002016 22
Figure 7: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Prescription Population, 20002016 23
Figure 8: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Revenue ($m), 20012017 24
Figure 9: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Revenue ($bn), 2001-2017 32
Figure 10: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Geographical Distribution of Revenues ($bn), 20012017 33
Figure 11: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Annual Cost of Therapy ($), 2001-2017 34
Figure 12: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Usage Patterns, 20002017 35
Figure 13: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Diseased Population, 20012017 36
Figure 14: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Treatment Seeking Population, 20012017 37
Figure 15: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Diagnosis Population, 20012017 38
Figure 16: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Prescription Population, 20012017 39
Figure 17: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Revenue ($bn), 2001-2017 41
Figure 18: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Geographical Distribution of Revenues ($bn), 20012017 43
Figure 19: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Annual Cost of Therapy ($), 2001-2017 44
Figure 20: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Usage Patterns, 20012017 45
Figure 21: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Diseased Population, 20012017 46
Figure 22: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Treatment Seeking Population, 20012017 47
Figure 23: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Diagnosis Population, 20012017 48
Figure 24: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Prescription Population, 20012017 49
Figure 25: Specialty Pharmaceutical Market, Alzheimers Disease, Global, Revenue ($bn), 2001-2017 51
Figure 26: Specialty Pharmaceutical Market, Alzheimers Disease, Global, Geographical Distribution of Revenues ($bn), 20012017 53
Figure 27: Specialty Pharmaceutical Market, Alzheimers Disease, Global, Annual Cost of Therapy ($), 2001-2017 54
Figure 28: Specialty Pharmaceutical Market, Alzheimers Disease, Global, Usage Patterns, 20012017 55
Figure 29: Specialty Pharmaceutical Market, Alzheimers Disease, Global, Diseased Population, 20012017 56
Figure 30: Specialty Pharmaceutical Market, Alzheimers Disease, Global, Treatment Seeking Population, 20012017 57
Figure 31: Specialty Pharmaceutical Market, Alzheimers Disease, Global, Diagnosis Population, 20012017 58
Figure 32: Specialty Pharmaceutical Market, Alzheimers Disease, Global, Prescription Population, 20012017 59
Figure 33: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Revenue ($bn), 2001-2017 61
Figure 34: Specialty Pharmaceutical Market Colorectal Cancer, Global, Geographical Distribution of Revenues ($bn), 20012017 63
Figure 35: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Annual Cost of Therapy ($), 2001-2017 64
Figure 36: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Usage Patterns, 20012017 65
Figure 37: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Diseased Population, 20012017 66
Figure 38: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Treatment Seeking Population, 20012017 67
Figure 39: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Diagnosis Population, 20012017 68
Figure 40: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Prescription Population, 20012017 69
Figure 41: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Revenue ($bn), 2001-2017 71
Figure 42: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2001-2017 73
Figure 43: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Usage Patterns, 20012017 74
Figure 44: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Diseased Population, 20012017 75
Figure 45: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Treatment Seeking Population, 20012017 76
Figure 46: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Diagnosis Population, 20012017 77
Figure 47: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Prescription Population, 20012017 78
Figure 48: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Geographical Distribution of Revenues ($bn), 20012017 79
Figure 49: Specialty Pharmaceutical Market, Epilepsy, Global, Revenue ($bn), 2001-2017 81
Figure 50: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($bn), 20012017 83
Figure 51: Specialty Pharmaceutical Market, Epilepsy, Global, Annual Cost of Therapy ($), 2001-2017 84
Figure 52: Specialty Pharmaceutical Market, Epilepsy, Global, Usage Patterns, 20012017 85
Figure 53: Specialty Pharmaceutical Market, Epilepsy, Global, Diseased Population, 20012017 86
Figure 54: Specialty Pharmaceutical Market, Epilepsy, Global, Treatment Seeking Population, 20012017 87
Figure 55: Specialty Pharmaceutical Market, , Epilepsy, Global, Diagnosis Population, 20012017 88
Figure 56: Specialty Pharmaceutical Market, Epilepsy, Global, Prescription Population, 20012017 89
Figure 57: Specialty Pharmaceutical Market, Glaucoma, Global, Revenue ($bn), 2001-2017 91
Figure 58: Specialty Pharmaceutical Market, Glaucoma, Global, Geographical Distribution of Revenues ($bn), 20012017 93
Figure 59: Specialty Pharmaceutical Market, Glaucoma, Global, Annual Cost of Therapy ($), 2001-2017 94
Figure 60: Specialty Pharmaceutical Market, Glaucoma, Global, Usage Patterns, 20012017 95
Figure 61: Specialty Pharmaceutical Market, Glaucoma, Global, Diseased Population, 20012017 96
Figure 62: Specialty Pharmaceutical Market, Glaucoma, Global, Treatment Seeking Population, 20012017 97
Figure 63: Specialty Pharmaceutical Market, Glaucoma, Global, Diagnosis Population, 20012017 98
Figure 64: Specialty Pharmaceutical Market, Glaucoma, Global, Prescription Population, 20012017 99
Figure 65: Specialty Pharmaceutical Market, Pipeline, Indication, 2010 102
Figure 66: Specialty Pharmaceutical Market, Pipeline, Phase Analysis, 2010 103
Figure 67: Specialty Pharmaceutical Market, Pipeline, By Indication, 2010 104
Figure 68: Specialty Pharmaceutical Market, Pipeline, HIV, 2010 105
Figure 69: Specialty Pharmaceutical Market, Pipeline, Age Related Macular Degeneration, 2010 112
Figure 70: Specialty Pharmaceutical Market, Pipeline Attention Deficit Hyperactive Disorder, 2010 114
Figure 71: Specialty Pharmaceutical Market, Pipeline, Alzheimers Disease, 2010 117
Figure 72: Specialty Pharmaceutical Market, Pipeline, Colorectal Cancer, 2010 122
Figure 73: Specialty Pharmaceutical Market, Pipeline, Rheumatoid Arthritis, 2010 129
Figure 74: Specialty Pharmaceutical Market, Pipeline, Epilepsy, 2010 133
Figure 75: Specialty Pharmaceutical Market, Pipeline, Glaucoma, 2010 139
Figure 76: Specialty Pharmaceutical Market, M&A, Year on Year, 2004 to 2010 142
Figure 77: Specialty Pharmaceutical Market, M&A, By Indication, 2004 to 2010 143
Figure 78: Specialty Pharmaceutical Market, M&A, Deal Type, 2004 to 2010 144
Figure 79: Specialty Pharmaceutical Market, Licensing Deals, Year on Year, 2004 to 2010 148
Figure 80: Specialty Pharmaceutical Market, Licensing Deals, By Indication, 2004 to 2010 148
Figure 81: Specialty Pharmaceutical Market, Co-development Deals, Year on Year, 2004 to 2010 155
Figure 82: Specialty Pharmaceutical Market, Co-development Deals, By Indication, 2004 to 2010 155
Figure 83: GBI Research Market Forecasting Model 166